News & Events

 

June 4th 2008

- Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors

April 14th 2008

- Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma

February 11-13 2008

- BIO CEO & Investor Conference 2008: On February 13th Semafore's CEO Ed Jacobs will present at 2:45 pm (ET) at the Waldorf-Astoria in the Park Avenue Suite

January 29th 2008

- Our budding biotech base turning heads (Interview with Semafore's CEO Mr. Edward Jacobs)